首页> 美国卫生研究院文献>PLoS Clinical Trials >In vivo therapeutic effect of combination treatment with metformin and Scutellaria baicalensis on maintaining bile acid homeostasis
【2h】

In vivo therapeutic effect of combination treatment with metformin and Scutellaria baicalensis on maintaining bile acid homeostasis

机译:二甲双胍和黄S联合治疗对维持胆汁酸稳态的体内治疗作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The radix of Scutellaria baicalensis (SB) is a herb widely used in traditional Chinese medicine to treat metabolic diseases. Several main components, including baicalin and wogonoside, possess anti-dyslipidemia, anti-obesity and anti-diabetic effects. We hypothesized that co-administration of SB extract and metformin exerts a better effect on obesity-induced insulin resistance and lipid metabolism than treatment with metformin alone. We compared the effect of metformin (100 mg/10 mL/kg/day) alone with co-administration of metformin (100 mg/5 mL/kg/day) and SB extract (200 mg/5 mL/kg/day) on Otsuka Long Evans Tokushima Fatty rats, a useful model of type II diabetes with obesity, and used Long-Evans Tokushima Otsuka rats as a control. Weight, fasting glucose, oral glucose tolerance test, intraperitoneal insulin tolerance test, and serum total cholesterol were measured after 12 weeks of drug administration. We observed a synergetic effect of metformin and SB on lowering cholesterol level by excretion of bile acid through feces. We found that this accompanied activation of FXR, CYP7A1 and LDLR genes and repression of HMGCR in the liver. Although there were no significant changes in BSH-active gut microbiota due to high variability, functional prediction with 16S sequences showed increased primary and secondary bile acid biosynthesis in the combination treatment group. Further study is needed to find the specific strains of bacteria which contribute to FXR-related cholesterol and bile acid regulations.
机译:黄cut(SB)是在中药中广泛用于治疗代谢性疾病的草药。几种主要成分,包括黄ical苷和Wogonoside,具有抗血脂异常,抗肥胖和抗糖尿病作用。我们假设与单独使用二甲双胍治疗相比,SB提取物和二甲双胍的共同给药对肥胖引起的胰岛素抵抗和脂质代谢具有更好的作用。我们比较了二甲双胍(100 mg / 10 mL / kg / day)与二甲双胍(100 mg / 5 mL / kg / day)和SB提取物(200 mg / 5 mL / kg / day)共同给药的效果。 Otsuka Long Evans Tokushima肥胖大鼠,一种有用的肥胖II型糖尿病模型,并使用Long-Evans Tokushima Otsuka大鼠作为对照。给药12周后,测量体重,空腹血糖,口服葡萄糖耐量试验,腹膜内胰岛素耐量试验和血清总胆固醇。我们观察到二甲双胍和SB对通过粪便排出胆汁酸来降低胆固醇水平的协同作用。我们发现这伴随着FXR,CYP7A1和LDLR基因的激活以及肝中HMGCR的抑制。尽管由于高变异性,BSH活性肠道菌群没有显着变化,但16S序列的功能预测显示,联合治疗组的一级和二级胆汁酸生物合成增加。需要进行进一步的研究,以找到有助于FXR相关胆固醇和胆汁酸调节的特定细菌菌株。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号